Tables are Turned: Teva Pharmaceutical Industries mostly makes generic drugs, but now finds itself acting like Big Pharma — defending the patent for a brand-name drug in order to stave off the threat of generic competition, the Wall Street Journal reports.
Mylan and Momenta are challenging the validity of Teva’s patents for the multiple-sclerosis drug Copaxone, hoping to sell generic copies before the patents expire in 2014 and 2015, the paper says.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1903
